Current literatures have uncovered the relationship of HDAC1 or miR-200b with the resistance of cancer cells to several commonly used drugs in LAD, such as cisplatin, paclitaxel, and gefitinib [41–46]. The gene discussed is HDAC1; the disease is cancer.